• Gubra flagged AbbVie’s detailed Phase 1 results for obesity candidate ABBV-295, presented at EASD 2026 in Milan.
• Data showed meaningful weight loss across dosing schedules, supporting continued development of the long-acting amylin program.
• Tolerability looked favorable, with side effects mainly mild and concentrated early in treatment.
• Findings supported less frequent dosing potential, strengthening differentiation from incretin-based weight-loss drugs.
• A Phase 2 trial in adults with overweight or obesity started in August 2026 under AbbVie’s lead.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gubra A/S published the original content used to generate this news brief on September 30, 2026, and is solely responsible for the information contained therein.